

Special Issue

Immunity to Influenza Viruses

Message from the Guest Editors

Influenza viruses remain a constant global threat with a significant health and socioeconomic impact every year, and have the potential to cause devastating pandemics. Despite this, current vaccines against influenza viruses are only modestly effective, require annual reformulation, and may not provide protection against emerging influenza viruses from animal reservoirs. Therefore, new vaccines are needed to combat influenza viruses. The aim of this Special Issue on “Immunity to Influenza Viruses” is to explore the immune response to influenza A and B viruses from humans and animals. Original research and comprehensive review articles presenting recent progress, challenges, and future perspectives in influenza immunity and vaccines are invited. These may cover influenza virus–host interactions, innate immunity to influenza viruses, antiviral restriction, immune evasion mechanisms, antibody and B-cell responses to influenza viruses, T-cell-mediated immune responses to influenza viruses and vaccines against influenza viruses, as well as immune responses and vaccines in high-risk groups.

Guest Editors

Dr. Marios Koutsakos

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3010, Australia

Dr. Sophie Valkenburg

Division of Public Health Laboratory Sciences, HKU Pasteur Research Pole, Hong Kong, China

Deadline for manuscript submissions

closed (31 March 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/52835

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).